A key committee reviewing India’s drug pricing reforms has been expanded to include patients, shifting the debate from numbers on paper to real healthcare impact. The move aims to make pricing decisions more grounded in affordability and access, potentially influencing how reforms are designed and implemented as stakeholders push for faster, fairer outcomes.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
